BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 23928760)

  • 21. Can cancer care lead the way toward a value-based future?
    Macmillan K
    Am J Manag Care; 2019 Dec; 25(12 Spec No.):SP377-SP378. PubMed ID: 31860249
    [No Abstract]   [Full Text] [Related]  

  • 22. [Economic evaluation in oncology].
    Schöffski O
    Med Klin (Munich); 2000 Jun; 95 Suppl 1():14-7. PubMed ID: 10941248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.
    Amir E; Seruga B; Martinez-Lopez J; Kwong R; Pandiella A; Tannock IF; Ocaña A
    J Clin Oncol; 2011 Jun; 29(18):2543-9. PubMed ID: 21606435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer care value-learning from others.
    Gamble RB
    Am J Manag Care; 2012 May; 18(3 Spec No.):SP139. PubMed ID: 22642284
    [No Abstract]   [Full Text] [Related]  

  • 25. Rewarding value creation to promote innovation in oncology: The importance of considering the global product life cycle.
    Garrison LP
    Oncologist; 2010; 15 Suppl 1():49-57. PubMed ID: 20237218
    [No Abstract]   [Full Text] [Related]  

  • 26. [Benefit-risk evaluation of new drugs as a basis for decisions on prioritization in hematology/oncology: methodical challenges and problem-solving strategies].
    Ludwig WD; Schildmann J
    Onkologie; 2011; 34 Suppl 1():6-10. PubMed ID: 21389762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tackling Cost: A Prescription for Spending Wisely.
    Tempero M
    J Natl Compr Canc Netw; 2019 Jun; 17(6):633. PubMed ID: 31200360
    [No Abstract]   [Full Text] [Related]  

  • 28. Can treatment costs be tamed?
    Malakoff D
    Science; 2011 Mar; 331(6024):1545-7. PubMed ID: 21436438
    [No Abstract]   [Full Text] [Related]  

  • 29. Market spiral pricing of cancer drugs.
    Light DW; Kantarjian H
    Cancer; 2013 Nov; 119(22):3900-2. PubMed ID: 24002792
    [No Abstract]   [Full Text] [Related]  

  • 30. Practical feasibility of outcomes research in oncology: lessons learned in assessing drug use and cost-effectiveness in The Netherlands.
    Franken MG; van Gils CW; Gaultney JG; Delwel GO; Goettsch W; Huijgens PC; Steenhoek A; Punt CJ; Koopman M; Redekop WK; Uyl-de Groot CA
    Eur J Cancer; 2013 Jan; 49(1):8-16. PubMed ID: 22809557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The high cost of cancer drugs and what we can do about it.
    Siddiqui M; Rajkumar SV
    Mayo Clin Proc; 2012 Oct; 87(10):935-43. PubMed ID: 23036669
    [No Abstract]   [Full Text] [Related]  

  • 32. Chemotherapy treatment options and policies.
    Breshears Wheeler J; Hanson K
    NCSL Legisbrief; 2012 May; 20(19):1-2. PubMed ID: 22666895
    [No Abstract]   [Full Text] [Related]  

  • 33. Bending the cost curve in cancer care.
    Good M; Good CB
    N Engl J Med; 2011 Aug; 365(7):674-5; author reply 675-6. PubMed ID: 21848478
    [No Abstract]   [Full Text] [Related]  

  • 34. US hospitals object to changes in Genentech drug distribution.
    Furlow B
    Lancet Oncol; 2014 Dec; 15(13):e591. PubMed ID: 25499290
    [No Abstract]   [Full Text] [Related]  

  • 35. How should we pay the piper when he's calling the tune? On the long-term affordability of cancer care in the United States.
    Ramsey SD
    J Clin Oncol; 2007 Jan; 25(2):175-9. PubMed ID: 17210936
    [No Abstract]   [Full Text] [Related]  

  • 36. Minimalism in oncology.
    The Lancet Oncology
    Lancet Oncol; 2018 May; 19(5):579. PubMed ID: 29726372
    [No Abstract]   [Full Text] [Related]  

  • 37. ASCO Rx for high drug costs: doctors and patients need to talk.
    Nicholas J
    J Natl Cancer Inst; 2009 Nov; 101(21):1441-4. PubMed ID: 19828870
    [No Abstract]   [Full Text] [Related]  

  • 38. A time of change in medical oncology. Problems created by the lack of coherence in Australia's health care system.
    Lowenthal RM
    Med J Aust; 1992 Jul; 157(1):28-30. PubMed ID: 1640887
    [No Abstract]   [Full Text] [Related]  

  • 39. Policy Statement on the 340B Drug Pricing Program by the American Society of Clinical Oncology.
    American Society of Clinical Oncology
    J Oncol Pract; 2014 Jul; 10(4):259-63. PubMed ID: 24737877
    [No Abstract]   [Full Text] [Related]  

  • 40. Outpatient cancer drug costs: changes, drivers, and the future.
    Halbert RJ; Zaher C; Wade S; Malin J; Lawless GD; Dubois RW
    Cancer; 2002 Feb; 94(4):1142-50. PubMed ID: 11920485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.